Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization
Author:
Funder
Canadian Institutes of Health Research
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology
Link
http://link.springer.com/content/pdf/10.1007/s10928-019-09634-7.pdf
Reference38 articles.
1. Stonebraker JS, Bolton-Maggs PHB, MichaelSoucie J, Walker I, Brooker M (2010) A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 16(1):20–32
2. Ahlberg Å (1965) Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand 36(sup77):3–132
3. Collins PW et al (2009) Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 7:413–420
4. Oldenburg J (2011) Prophylaxis in bleeding disorders. Thromb Res 127:S14–S17
5. Berntorp E, Spotts G, Patrone L, Ewenstein B (2014) Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method. Biol Targets Ther 8:115
Cited by 24 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Development and internal validation of a clinical prediction model for individualized dosing of BAY 81-8973, A full-length recombinant factor VIII, in pediatric patients with haemophilia A;Thrombosis Research;2023-12
2. Clotting factor activity levels and bleeding risk in people with haemophilia playing sports;Haemophilia;2023-05-24
3. Dosing for Personalized Prophylaxis in Hemophilia A Highly Varies on the Underlying Population Pharmacokinetic Models;Therapeutic Drug Monitoring;2022-10
4. Application of SHAP values for inferring the optimal functional form of covariates in pharmacokinetic modeling;CPT: Pharmacometrics & Systems Pharmacology;2022-06-24
5. Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia;HemaSphere;2022-03-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3